Retatrutide's 24% weight loss is still pending FDA approval. But the drug class it belongs to has powerful options on the market right now. Here's how to rank and choose between them.
Retatrutide will almost certainly be one of the most significant metabolic drugs of the decade. The 24.2% mean body weight reduction in Phase 2 is a number that has never been seen in a randomized controlled trial. The Phase 3 TRIUMPH program is reading out. FDA approval is expected in late 2026 or early 2027. But it is not available yet — and for people with metabolic dysfunction who want to intervene now, waiting is its own risk.
The good news: the drug class that produced retatrutide is already well represented on the market, and the currently available options are genuinely powerful. Understanding how they differ from retatrutide, and from each other, is the difference between choosing the right tool for your situation and settling for the wrong one.
This guide ranks the five best commercially available alternatives in 2026 and explains how to choose between them.
Retatrutide's uniqueness comes from its glucagon receptor agonism — the third receptor activation that no other approved drug currently includes. The GLP-1 and GIP components are replicated by tirzepatide. The pure GLP-1 component is replicated by semaglutide. The glucagon component — responsible for retatrutide's extraordinary liver fat reduction and enhanced energy expenditure — is not available in any FDA-approved drug as of 2026.
That's the honest starting point. You cannot fully replicate retatrutide. What you can do is access a substantial portion of its effect profile through currently available options — and for most people with metabolic dysfunction, the currently available options are more than sufficient to produce meaningful, measurable results.